Avenue Therapeutics, Inc. (ATXI) EPS Estimated At $-0.39

October 14, 2018 - By Darrin Black

Analysts expect Avenue Therapeutics, Inc. (NASDAQ:ATXI) to report $-0.39 EPS on November, 8.They anticipate $0.09 EPS change or 30.00 % from last quarter’s $-0.3 EPS. After having $-0.45 EPS previously, Avenue Therapeutics, Inc.’s analysts see -13.33 % EPS growth. The stock increased 9.17% or $0.31 during the last trading session, reaching $3.69. About 918,332 shares traded or 1749.83% up from the average. Avenue Therapeutics, Inc. (NASDAQ:ATXI) has declined 45.48% since October 14, 2017 and is downtrending. It has underperformed by 61.10% the S&P500.

Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes an intravenous formulation of tramadol HCI principally for use in the acute/intensive care hospital setting. The company has market cap of $38.95 million. The Company’s product candidate is IV Tramadol for the treatment of post-operative pain. It currently has negative earnings. The firm was founded in 2015 and is based in New York, New York.

More notable recent Avenue Therapeutics, Inc. (NASDAQ:ATXI) news were published by: Benzinga.com which released: “The Daily Biotech Pulse: Affimed’s Cancer Drug Placed On Clinical Hold, Celgene’s Positive Scalp Psoriasis Trial” on October 09, 2018, also Seekingalpha.com with their article: “Weekly market movement wrap” published on October 13, 2018, Benzinga.com published: “20 Stocks Moving In Friday’s Pre-Market Session” on October 12, 2018. More interesting news about Avenue Therapeutics, Inc. (NASDAQ:ATXI) were released by: Benzinga.com and their article: “41 Stocks Moving In Friday’s Mid-Day Session” published on October 12, 2018 as well as Benzinga.com‘s news article titled: “44 Biggest Movers From Yesterday” with publication date: October 12, 2018.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>